Abdominal ultrasound and its significant role in colon cancer. The advantage of its dynamic nature: using respiratory movements to assess neoplasia relations to adjacent organs.

A 58-year-old, otherwise healthy male presented to the Emergency Room due to a 24-hour-long bloody diarrhea and constitutional syndrome. Colonoscopy confirmed the presence of a colonic neoplasia. A CT scan revealed an irregular surface and poorly delimited hypodensity of liver segment 5, next to the neoplasia, with malignant infiltration being impossible to rule out.

Concurrent hepatic and renal angiomyolipomas in tuberous sclerosis complex

No disponible

Concurrent hepatic and renal angiomyolipomas in tuberous sclerosis complex.

Tuberous sclerosis complex (TSC) is a rare disease which is characterized by widespread of a variety of benign tumors in multiple organs. Renal angiomyolipomas (AMLs) are the primary cause of morbidity in TSC due to anemia, renal failure or spontaneous bleeding. In contrast, the hepatic involvement is unusual and it is infrequently described in literature.

Características y supervivencia del carcinoma hepatocelular en hígado no cirrótico / Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver

Introducción: las características, cribado, y supervivencia del carcinoma hepatocelular (CHC) en pacientes sin cirrosis están menos definidas. Pacientes y métodos: se recogieron retrospectivamente (enero 2004-octubre 2018) los pacientes con CHC diagnosticados citohistológicamente sin cirrosis. Analizamos sus características, tratamiento y supervivencia. Resultados: de los 332 pacientes con CHC, 25 cumplían los criterios de inclusión (7,5%). Varones: 76%. Mediana de edad: 69,9 años. El virus de la hepatitis B (VHB) fue el principal agente etiológico de hepatopatía: 32%, seguido de la esteatohepatitis no alcohólica (EHNA): 20%. La fibrosis fue leve (0-1) en el 44%. El nódulo se descubrió por ecografía de seguimiento en el 32%, en el 60% fue casual, y 8% por síntomas. El estadio de Barcelona Clinic Liver Cancer (BCLC) fue 0 en 4%, A 88%, B 4%, y C 4%. El tratamiento inicial mayoritario fue la resección quirúrgica (76%), 8% rechazaron tratamiento, y se realizó etanolización, quimioembolización, sorafenib y tratamiento sintomático en el 4% para cada uno. El 21% de los pacientes operados presentó complicaciones, la mitad severas. La mediana de seguimiento fue 22,2 (2,9-150,6) meses, con remisión en el 56%. Mediana de supervivencia global: 57,4 +/- 29,8 meses. Supervivencia acumulada: 84% al año, 61,6% a los 3 años y 47,9% a los 5 años. Conclusión: el 7,5% de los CHC se desarrollaron sin cirrosis. El grado de fibrosis fue leve en casi la mitad. El VHB fue la causa principal, seguida de EHNA. El estadio de BCLC principal al diagnóstico fue el precoz. La cirugía fue el tratamiento más habitual. La supervivencia a los 5 años fue cercana al 50%

Introduction: the characteristics, screening, and survival of hepatocellular carcinoma (HCC) for patients without cirrhosis have not been fully studied. Methods: A retrospective cohort study was performed in non-cirrhotic patients with histological HCC, between January 2004 and October 2018. Their characteristics, treatment, follow-up and overall survival were described. Results: 25 of the 332 patients with HCC met the inclusion criteria (7.5%), 76% were males and the median age was 69.9 years. The main etiology of liver disease was the hepatitis B virus (HBV) (32%), followed by non-alcoholic steatohepatitis (NASH) (20%). Liver fibrosis was mild (0-1) in 44% of cases. The nodule was diagnosed by ultrasonography in 32% of cases, 60% were found incidentally and 8% due to clinical symptoms. The Barcelona Clinic Liver Cancer (BCLC) staging was 0 in 4% of cases, A in 88%, B in 4% and C in 4%. The main initial treatment was surgical resection (76%) and 8% refused to be treated. Percutaneous ethanol injection, chemoembolization, sorafenib and palliative care were each performed in 4% of cases. There were some complications in 21% of patients treated with surgery, half of them were severe. The median follow-up was 22.2 (2.9-150.6) months and 56% were in remission and the median overall survival was 57.4 +/- 29.8 months. The overall cumulative survival at 1, 3 and 5 years was 84%, 61.6% and 47.9%, respectively. Conclusion: 7.5% of HCC presented without cirrhosis and almost half of patients had mild fibrosis. HBV was the main cause of HCC, followed by NASH. The most frequent BCLC stage at diagnosis was early stage and surgery was the most common treatment. Overall cumulative survival at 5 years was almost 50%

Formación en Ecografía de los Médicos Residentes de Aparato Digestivo: encuesta y proyecto docente de la Asociación Española de Ecografía Digestiva / Training in Ultrasound for Resident Physicians in Gastroenterology: a survey and training project by the Spanish Association of Digestive Ultrasound (Asociación Española de Ecografía Digestiva - AEED)

Antecedentes: el programa de formación de la Especialidad de Aparato Digestivo, que deben seguir los Médicos Internos y Residentes de Aparato Digestivo, obliga a que estos dominen la ecografía digestiva diagnóstica y terapéutica. Métodos: la Asociación Española de Ecografía Digestiva ha realizado una encuesta a los 93 Servicios de Aparato Digestivo con programa de formación de Médicos Internos y Residentes de Aparato Digestivo para conocer la situación exacta de la docencia en ecografía digestiva. Resultados: solo 31 de los 93 (33%) Servicios de Aparato Digestivo podían dar formación en Ecografía Digestiva. Un 33% (48 de 148) de los Médicos Internos y Residentes de Aparato Digestivo no recibían una formación específica en ecografía digestiva, y otro 31% (46 de 148) recibían una formación específica pero en condiciones mejorables. Estas deficiencias afectaban a todas las Comunidades Autónomas de España, 8 de las cuales carecían totalmente de Servicios de Aparato Digestivo con capacidad para formar en Ecografía Digestiva. Conclusiones: existe un déficit importante de Servicios de Aparato Digestivo que puedan dar formación en Ecografía Digestiva a los Médicos Internos y Residentes de Aparato Digestivo y ello provoca una notable desigualdad formativa. Hasta que se pueda revertir esta situación, la Asociación Española de Ecografía Digestiva ha diseñado un proyecto formativo en Ecografía Digestiva dirigido a dar una docencia adecuada a todos los Médicos Internos y Residentes de Aparato Digestivo que lo necesiten

Background: the training program of the gastroenterology specialty that is mandatory for resident physicians, obliges them to be proficient in diagnostic and therapeutic digestive ultrasound tools. Methodology: the Asociación Española de Ecografía Digestiva (AEED) performed a survey of the 93 Departments of Gastroenterology with training programs for resident physicians in gastroenterology, in order to assess the exact situation of training in digestive ultrasound in Spain. Results: only 31 of the 93 (33%) Departments of Gastroenterology were able to provide training in Digestive Ultrasound. Moreover, 33% (48 out of 148) of the residents in gastroenterology did not receive specific training in digestive ultrasound. Whereas, 31% (46 out of 148) had received some specific training, but with ample room for improvement. These deficiencies were spread throughout the Spanish regions (Autonomous Communities) in an uneven manner, with almost half totally lacking gastroenterology departments that were capable of providing digestive ultrasound training. Conclusions: there is a significant deficit of gastroenterology departments capable of providing training in digestive ultrasound to residents, causing a significant training inequality. Until this situation can be reversed, the AEED has designed a training project in digestive ultrasound aimed at providing adequate training to all residents in gastroenterology as required

Training in Ultrasound for Resident Physicians in Gastroenterology: a survey and training project by the Spanish Association of Digestive Ultrasound (Asociación Española de Ecografía Digestiva - AEED).

BACKGROUND: the training program of the gastroenterology specialty that is mandatory for resident physicians, obliges them to be proficient in diagnostic and therapeutic digestive ultrasound tools. METHODOLOGY: the Asociación Española de Ecografía Digestiva (AEED) performed a survey of the 93 Departments of Gastroenterology with training programs for resident physicians in gastroenterology, in order to assess the exact situation of training in digestive ultrasound in Spain. RESULTS: only 31 of the 93 (33%) Departments of Gastroenterology were able to provide training in Digestive Ultrasound. Moreover, 33% (48 out of 148) of the residents in gastroenterology did not receive specific training in digestive ultrasound. Whereas, 31% (46 out of 148) had received some specific training, but with ample room for improvement. These deficiencies were spread throughout the Spanish regions (Autonomous Communities) in an uneven manner, with almost half totally lacking gastroenterology departments that were capable of providing digestive ultrasound training. CONCLUSIONS: there is a significant deficit of gastroenterology departments capable of providing training in digestive ultrasound to residents, causing a significant training inequality. Until this situation can be reversed, the AEED has designed a training project in digestive ultrasound aimed at providing adequate training to all residents in gastroenterology as required.

Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver.

INTRODUCTION: the characteristics, screening, and survival of hepatocellular carcinoma (HCC) for patients without cirrhosis have not been fully studied. METHODS: A retrospective cohort study was performed in non-cirrhotic patients with histological HCC, between January 2004 and October 2018. Their characteristics, treatment, follow-up and overall survival were described. RESULTS: 25 of the 332 patients with HCC met the inclusion criteria (7.5%), 76% were males and the median age was 69.9 years. The main etiology of liver disease was the hepatitis B virus (HBV) (32%), followed by non-alcoholic steatohepatitis (NASH) (20%). Liver fibrosis was mild (0-1) in 44% of cases. The nodule was diagnosed by ultrasonography in 32% of cases, 60% were found incidentally and 8% due to clinical symptoms. The Barcelona Clinic Liver Cancer (BCLC) staging was 0 in 4% of cases, A in 88%, B in 4% and C in 4%. The main initial treatment was surgical resection (76%) and 8% refused to be treated. Percutaneous ethanol injection, chemoembolization, sorafenib and palliative care were each performed in 4% of cases. There were some complications in 21% of patients treated with surgery, half of them were severe. The median follow-up was 22.2 (2.9-150.6) months and 56% were in remission and the median overall survival was 57.4 ± 29.8 months. The overall cumulative survival at 1, 3 and 5 years was 84%, 61.6% and 47.9%, respectively. CONCLUSION: 7.5% of HCC presented without cirrhosis and almost half of patients had mild fibrosis. HBV was the main cause of HCC, followed by NASH. The most frequent BCLC stage at diagnosis was early stage and surgery was the most common treatment. Overall cumulative survival at 5 years was almost 50%.

Tratamiento percutáneo del carcinoma hepatocelular en pacientes con edad avanzada en la práctica clínica / Percutaneous ablation of hepatocellular carcinoma in older patients in clinical practice

INTRODUCCIÓN: Existe un alto porcentaje de pacientes con carcinoma hepatocelular (CHC) en estadio precoz con edad avanzada, que son potenciales candidatos a tratamiento percutáneo. MATERIAL Y MÉTODO: Evaluamos prospectivamente los datos de pacientes con CHC mayores de 70 años. Describimos sus características y el tratamiento pautado, así como la respuesta, las complicaciones y la supervivencia de los tratados con radiofrecuencia (RF) y/o inyección percutánea de alcohol (IPA). RESULTADOS: De los 194 pacientes con CHC, 84 eran mayores de 70 años (43,3%). La edad media era 76,8 ± 4,5 años. El 75% eran varones. El 91,7% eran cirróticos. El 61,9% se descubrió por cribado. Se diagnosticaron en estadio precoz (0-A) de Barcelona Clinic Liver Cancer el 60,7%, en B, el 19%, en C, el 12%, y en D, el 8,3%. El 38,2% recibió tratamiento potencialmente curativo (4,8% resección, 22,6% IPA, 4,8% RF, 6% IPA + RF), el 20,2%, quimioembolización, el 3,6%, sorafenib, el 25% no fue candidato a tratamiento, y el 13% rechazó el tratamiento recomendado. La mediana de seguimiento desde que recibieron el tratamiento percutáneo fue de 23 (IIC 14,2-40,6) meses. La media del número de sesiones de IPA fue de 3,5 ± 2,2 y de RF 1,8 ± 1,6. Hubo un 4% de complicaciones por sesión. Permanecieron en remisión el 35,7%. La mediana de supervivencia fue de 45,7 meses (IC 95% 20,8-70,6). CONCLUSIONES: El 43,3% de nuestros pacientes con CHC tenían una edad avanzada. Más de la mitad se diagnosticaron en estadio precoz. En un tercio se realizó tratamiento percutáneo, con un 35,7% de remisión y complicaciones poco frecuentes. Por lo tanto, este tipo de pacientes deben evaluarse para tratamiento percutáneo

INTRODUCTION: A high percentage of older patients with early-stage hepatocellular carcinoma (HCC) are potential candidates for percutaneous ablation.Material and methods We prospectively assessed data from patients older than 70 years with HCC. We determined their demographic and clinical characteristics, the treatment provided and the response, complications and survival among those treated with radiofrequency ablation (RFA) and/or percutaneous ethanol injection (PEI). RESULTS: Of 194 patients with HCC, 84 were older than 70 years (43.3%). The mean age was 76.8 ± 4.5 years. Seventy-five percent were male and 91.7% had cirrhosis. Cancer was initially identified by a surveillance program in 61.9%. According to the Barcelona Clinic Liver Cancer staging system, 60.7% were classified as having early stage cancer (0-A), 19% as stage B, 12% as stage C, and 8.3% as stage D. Potentially curative initial treatment was provided in 38.2% (surgical resection in 4.8%, PEI in 22.6%, RFA in 4.8%, PEI + RFA in 6%), transarterial chemoembolization in 20.2%, and sorafenib in 3.6%. Twenty-five percent of patients were not treatment candidates and 13% refused the recommended treatment. The median follow-up after percutaneous ablation was 23 months (IQR 14.2-40.6). The mean number of sessions was 3.5 ± 2.2 for PEI and 1.8 ± 1.6 for RFA. The complications rate per session was 4%. Remission was achieved in 35.7%. The overall median survival was 45.7 months (95% CI 20.8-70.6). CONCLUSIONS: Almost half of the patients with HCC in our sample were elderly and more than half were diagnosed at an early stage. Percutaneous ablation was performed in one-third of the sample, achieving remission in 37.5%. There were few complications. Therefore, these patients should be assessed for percutaneous ablation

[Percutaneous ablation of hepatocellular carcinoma in older patients in clinical practice]. / Tratamiento percutáneo del carcinoma hepatocelular en pacientes con edad avanzada en la práctica clínica.

INTRODUCTION: A high percentage of older patients with early-stage hepatocellular carcinoma (HCC) are potential candidates for percutaneous ablation. MATERIAL AND METHODS: We prospectively assessed data from patients older than 70 years with HCC. We determined their demographic and clinical characteristics, the treatment provided and the response, complications and survival among those treated with radiofrequency ablation (RFA) and/or percutaneous ethanol injection (PEI). RESULTS: Of 194 patients with HCC, 84 were older than 70 years (43.3%). The mean age was 76.8 ± 4.5 years. Seventy-five percent were male and 91.7% had cirrhosis. Cancer was initially identified by a surveillance program in 61.9%. According to the Barcelona Clinic Liver Cancer staging system, 60.7% were classified as having early stage cancer (0-A), 19% as stage B, 12% as stage C, and 8.3% as stage D. Potentially curative initial treatment was provided in 38.2% (surgical resection in 4.8%, PEI in 22.6%, RFA in 4.8%, PEI+RFA in 6%), transarterial chemoembolization in 20.2%, and sorafenib in 3.6%. Twenty-five percent of patients were not treatment candidates and 13% refused the recommended treatment. The median follow-up after percutaneous ablation was 23 months (IQR 14.2-40.6). The mean number of sessions was 3.5 ± 2.2 for PEI and 1.8 ± 1.6 for RFA. The complications rate per session was 4%. Remission was achieved in 35.7%. The overall median survival was 45.7 months (95% CI 20.8-70.6). CONCLUSIONS: Almost half of the patients with HCC in our sample were elderly and more than half were diagnosed at an early stage. Percutaneous ablation was performed in one-third of the sample, achieving remission in 37.5%. There were few complications. Therefore, these patients should be assessed for percutaneous ablation.

Características clínicas, estadificación y tratamiento de los pacientes con carcinoma hepatocelular en la práctica clínica. Estudio prospectivo de una serie de 136 pacientes / Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients

El carcinoma hepatocelular (CHC) es la causa más frecuente de muerte en pacientes cirróticos. No existen en España series prospectivas de un solo centro terciario sobre estos pacientes. Material y método Estudio prospectivo de pacientes diagnosticados de CHC. Se recogieron sus características clínicas y epidemiológicas, metodología diagnóstica, estadificación según el sistema de Barcelona Clinic Liver Cancer (BCLC) y tratamiento. Resultados Se incluyeron 136 pacientes. El 80,9% fueron varones. La edad media fue de 66,62 ± 11,68 años. El 91,2% eran cirróticos. En el 38,97% la etiología de la hepatopatía fue el virus de la hepatitis C (VHC). La sospecha diagnóstica se estableció mediante programa de cribado en un 63,2%. Los criterios no invasivos American Association for the Study of Liver Diseases (AASLD) fueron el principal método diagnóstico (73,5%). Se diagnosticaron en estadio precoz (0-A) el 58,1%, en B el 21,3%, en C el 12,5% y en D el 8,1%. Los pacientes en estadio precoz habían seguido una estrategia de cribado más frecuentemente que aquellos en estadio no precoz (79,75 versus 44,35%, p < 0,001). El 45,58% recibió un tratamiento inicial potencialmente curativo, siendo el más frecuente la inyección percutánea de alcohol (23,13%).ConclusionesLa mayoría de los pacientes con CHC en nuestro centro presentan una cirrosis hepática de base, cuya etiología más frecuente es el VHC. El cribado de los pacientes en riesgo permite diagnosticar un mayor número en estadio precoz, lo que se consigue en más de la mitad de los casos. El tratamiento inicial más empleado fue el percutáneo(AU)

Abstract Hepatocellular carcinoma (HCC) is the most frequent cause of mortality in patients with liver cirrhosis. There are no prospective series from a single tertiary hospital in Spain.Material and Methods We performed a prospective study of patients with HCC in our center. Clinical and epidemiological characteristics, diagnostic method, staging according to the Barcelona Clinic Liver Cancer (BCLC) system and treatment were analyzed.ResultsA total of 136 patients were included (80.9% men). The mean age was 66.62±11.68 years and 91.2% were cirrhotic. Hepatitis C virus (HCV) was the leading cause of liver disease (38.97%). The suspected diagnosis was established by a surveillance program in 63.2%. Noninvasive American Association criteria for the Study of Liver Diseases (AASLD) were the main diagnostic method (73.5%). According to the BCLC, 58.1% were in the early stage (0-A), 21.3% in stage B, 12.5% in stage C and 8.1% in stage D. Early stage patients had followed a surveillance program more frequently than those with non-early stages (79.75% versus 44.35%, p <0.001). Potentially curative initial treatment was used in 45.58%, the most common treatment being percutaneous ethanol injection (23.13%).ConclusionsMost patients with HCC in our hospital have cirrhosis, the most frequent cause being HCV. HCC surveillance in at-risk patients could increase diagnosis of HCC at an early stage. We achieved an early diagnosis in more than half of cases. The most common initial treatment was percutaneous th(AU)

[Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients]. / Características clínicas, estadificación y tratamiento de los pacientes con carcinoma hepatocelular en la práctica clínica. Estudio prospectivo de una serie de 136 pacientes.

UNLABELLED: Hepatocellular carcinoma (HCC) is the most frequent cause of mortality in patients with liver cirrhosis. There are no prospective series from a single tertiary hospital in Spain. MATERIAL AND METHODS: We performed a prospective study of patients with HCC in our center. Clinical and epidemiological characteristics, diagnostic method, staging according to the Barcelona Clinic Liver Cancer (BCLC) system and treatment were analyzed. RESULTS: A total of 136 patients were included (80.9% men). The mean age was 66.62 ± 11.68 years and 91.2% were cirrhotic. Hepatitis C virus (HCV) was the leading cause of liver disease (38.97%). The suspected diagnosis was established by a surveillance program in 63.2%. Noninvasive American Association criteria for the Study of Liver Diseases (AASLD) were the main diagnostic method (73.5%). According to the BCLC, 58.1% were in the early stage (0-A), 21.3% in stage B, 12.5% in stage C and 8.1% in stage D. Early stage patients had followed a surveillance program more frequently than those with non-early stages (79.75% versus 44.35%, p <0.001). Potentially curative initial treatment was used in 45.58%, the most common treatment being percutaneous ethanol injection (23.13%). CONCLUSIONS: Most patients with HCC in our hospital have cirrhosis, the most frequent cause being HCV. HCC surveillance in at-risk patients could increase diagnosis of HCC at an early stage. We achieved an early diagnosis in more than half of cases. The most common initial treatment was percutaneous therapy.

[Utility of endoscopic ultrasonography in the etiological diagnosis of patients with acute idiopathic pancreatitis]. / Utilidad de la ecoendoscopia en el diagnóstico etiológico de los pacientes con pancreatitis aguda idiopática.

UNLABELLED: The aim of this study was to evaluate the utility of endoscopic ultrasonography in the etiological diagnosis of patients initially diagnosed with acute idiopathic pancreatitis and to determine the clinical and laboratory factors related to the results of this technique. MATERIAL AND METHODS: We studied 73 patients initially diagnosed with acute idiopathic pancreatitis and referred to our service for biliopancreatic endoscopic ultrasonography. A positive result was considered to be identification of at least one possible cause of pancreatitis, excluding patients in whom the only echoendoscopic finding was chronic pancreatitis. The clinical characteristics and clinical course of these patients were compared with the results of the technique. RESULTS: Endoscopic ultrasonography diagnosed at least one possible cause of acute pancreatitis in 32 patients (44%). The most frequent diagnoses were cholelithiasis (16%) and biliary sludge (20%). The diagnostic yield of endoscopic ultrasonography was lower in patients with prior cholecystectomy (16% vs. 49%; p=0.037) while a positive result was more likely in patients with elevated glutamyl oxaloacetic transaminase (GOT) or glutamyl pyruvic transaminase (GPT) levels at diagnosis of acute pancreatitis (GOT: 68 vs. 31%; p=0.002; GPT: 63 vs. 26%; p=0.001). No differences were found in diagnostic yield according to whether endoscopic ultrasonography was performed during the first episode of pancreatitis (48%) or in recurrent episodes (37%) (p=0.40). Over a mean follow-up period of 28 months, recurrence of new episodes of pancreatitis was significantly lower in patients with an etiological diagnosis (3 vs. 22%; p=0.02). CONCLUSIONS: Endoscopic ultrasonography is a useful technique in the etiological diagnosis of acute pancreatitis of unknown origin, especially in patients with elevated transaminase levels and/or without cholecystectomy. This technique should be used in the first episode of acute idiopathic pancreatitis.

[Value of contrast-enhanced ultrasound in the diagnosis of hepatocarcinoma in focal lesions detected in patients with liver disease]. / Valor de los contrastes ecográficos en el diagnóstico de hepatocarcinoma en lesiones ocupantes de espacio detectadas en pacientes con hepatopatía.

OBJECTIVE: To assess the value of contrast-enhanced ultrasound in the detection of arterial hypervascularity as a diagnostic criterion of hepatocellular carcinoma (HCC) in patients with focal lesions and liver disease. PATIENTS AND METHODS: This prospective study included patients with chronic liver disease and focal liver lesions on ultrasound (US) examination. SonoVue was used as contrast agent. We employed a US imaging technique with contrast-specific software operating at a low mechanical index (< 0.14) (Hitachi EUB 6500). The contrast enhancement pattern was analyzed during the arterial phase and classified as diffuse (homogeneous or heterogeneous), peripheral, adjacent parenchyma-like enhancement, and absent. The diagnostic procedure was completed by combined study with computed tomography, magnetic resonance imaging, histologic data and clinical features. RESULTS: A total of 23 nodules in 22 patients were included in the study (one patient had two different US lesions). The final diagnosis was hepatocellular carcinoma (HCC) in 12 patients, benign lesions in nine, metastases in one and cholangiocarcinoma in one. In the 10 patients with diffuse contrast enhancement, the lesion was malignant and in the eight patients with diffuse homogeneous enhancement, the lesion was a HCC. Seventy-five percent of the patients with HCC had a diffuse enhancement pattern during the arterial phase. This pattern involved malignancy with 71.4% sensitivity, 100% specificity, 100% positive predictive value, 69.2% negative predictive value, and 82.6% accuracy. The diffuse homogeneous pattern involved HCC with 66.7% sensitivity, 100% specificity, 100% positive predictive value, 73.3% negative predictive value and 82.6% accuracy. CONCLUSIONS: Contrast-enhanced US with SonoVue allows the vascularity of focal liver lesions to be assessed. In our study, 75% of patients with HCC showed arterial hypervascularity. A diffuse homogeneous enhancement pattern during the arterial phase was highly specific to HCC. In cirrhotic patients, this arterial pattern could avoid the need for further investigations, although clinical staging should be completed with another diagnostic test.

Valor de los contrastes ecográficos en el diagnóstico de hepatocarcinoma en lesiones ocupantes de espacio detectadas en pacientes con hepatopatía / Value of contrast-enhanced ultrasound in the diagnosis of hepatocarcinoma in focal lesions detected in patients with liver disease

Objetivo: Determinar la utilidad de la ecografía con contraste en la detección de hipervascularización arterial como criterio diagnóstico de carcinoma hepatocelular (CHC) en lesiones ocupantes de espacio (LOE) de pacientes con hepatopatía. Pacientes y métodos: Estudio prospectivo en el que se incluyen pacientes con hepatopatía crónica a los que se detectó alguna LOE mediante ecografía. Como potenciador se administró un contraste de segunda generación (SonoVue®). Se utilizó un ecógrafo Hitachi EUB 6500 con un programa específico para potenciadores, y se empleó un índice mecánico inferior a 0,14. Se analizó el patrón de captación en fase arterial, clasificándose en patrón difuso (homogéneo o heterogéneo), periférico, captación similar al parénquima circundante y ausencia de captación. El diagnóstico definitivo se confirmó mediante el estudio combinado de tomografía computarizada, resonancia magnética y análisis histológico, junto con la evolución clínica. Resultados: Se incluyen 23 lesiones en 22 pacientes (uno presentó 2 lesiones de características ecográficas diferentes). El diagnóstico final fue: CHC en 12 casos, lesiones benignas en 9, metástasis en uno y colangiocarcinoma en otro caso. Todos los casos que presentaron un patrón difuso con el contraste tenían una lesión maligna, y los 8 casos con patrón difuso homogéneo tenían un CHC. El 75% de los pacientes con CHC presentó una hipervascularización arterial con un patrón difuso tras el contraste. Este patrón difuso presentó una sensibilidad del 71,4%, especificidad del 100%, valor predictivo positivo (VPP) del 100%, valor predictivo negativo (VPN) del 69,2% y exactitud del 82,6% para el diagnóstico de malignidad. El patrón difuso homogéneo presentó una sensibilidad del 66,7%, una especificidad del 100%, un VPP del 100%, un VPN del 73,3% y una exactitud del 82,6% para el diagnóstico de CHC. Conclusiones: La utilización de la ecografía con contraste de segunda generación facilita una caracterización vascular inmediata de la lesión. En nuestro estudio se detecta una hipervascularización arterial en el 75% de los pacientes con CHC. Un patrón de realce difuso homogéneo es muy específico de CHC. Creemos que la detección de este tipo de patrón en un paciente con cirrosis haría innecesaria la utilización de más pruebas de imagen para el diagnóstico, si bien el estudio de extensión debe completarse con otra técnica

Objective: To assess the value of contrast-enhanced ultrasound in the detection of arterial hypervascularity as a diagnostic criterion of hepatocellular carcinoma (HCC) in patients with focal lesions and liver disease. Patients and methods: This prospective study included patients with chronic liver disease and focal liver lesions on ultrasound (US) examination. SonoVue® was used as contrast agent. We employed a US imaging technique with contrast-specific software operating at a low mechanical index (< 0.14) (Hitachi EUB 6500). The contrast enhancement pattern was analyzed during the arterial phase and classified as diffuse (homogeneous or heterogeneous), peripheral, adjacent parenchyma-like enhancement, and absent. The diagnostic procedure was completed by combined study with computed tomography, magnetic resonance imaging, histologic data and clinical features. Results: A total of 23 nodules in 22 patients were included in the study (one patient had two different US lesions). The final diagnosis was hepatocellular carcinoma (HCC) in 12 patients, benign lesions in nine, metastases in one and cholangiocarcinoma in one. In the 10 patients with diffuse contrast enhancement, the lesion was malignant and in the eight patients with diffuse homogeneous enhancement, the lesion was a HCC. Seventy-five percent of the patients with HCC had a diffuse enhancement pattern during the arterial phase. This pattern involved malignancy with 71.4% sensitivity, 100% specificity, 100% positive predictive value, 69.2% negative predictive value, and 82.6% accuracy. The diffuse homogeneous pattern involved HCC with 66.7% sensitivity, 100% specificity, 100% positive predictive value, 73.3% negative predictive value and 82.6% accuracy. Conclusions: Contrast-enhanced US with SonoVue® allows the vascularity of focal liver lesions to be assessed. In our study, 75% of patients with HCC showed arterial hypervascularity. A diffuse homogeneous enhancement pattern during the arterial phase was highly specific to HCC. In cirrhotic patients, this arterial pattern could avoid the need for further investigations, although clinical staging should be completed with another diagnostic test

[Contribution of endoscopic ultrasound to the diagnosis of pancreatic metastases from renal carcinoma. Apropos of two cases]. / Aportación de la ecoendoscopia al diagnóstico de las metástasis pancreáticas del carcinoma renal: a propósito de dos casos.

Pancreatic metastases represent 2% of pancreatic tumors. The neoplasms most frequently metastasizing to the pancreas are breast, lung, melanoma and kidney tumors. We present the cases of two patients with pancreatic metastases from renal carcinoma diagnosed 4 and 8 years after the diagnosis and surgical treatment of the primary renal tumor. In both patients, endoscopic ultrasound was useful in the detection and characterization of these pancreatic lesions and allowed fine-needle aspiration for cytological study to be performed.

Aportación de la ecoendoscopia al diagnóstico de las metástasis pancreáticas del carcinoma renal: a propósito de dos casos / Contribution of endoscopic ultrasound to the diagnosis of pancreatic metastases from renal carcinoma. Apropos of two cases

Las metástasis pancreáticas representan el 2% de los tumores pancreáticos. Las neoplasias que con más frecuencia metastatizan en el páncreas son: mama, pulmón, melanoma y riñón. Presentamos los casos clínicos de 2 pacientes con metástasis pancreáticas de carcinoma renal detectadas a los 4 y 8 años del diagnóstico e intervención quirúrgica del tumor primario renal. En ambos casos la ecoendoscopia resultó ser una técnica útil en la detección y la caracterización de estas lesiones pancreáticas, y permitió la realización de una punción para el estudio citológico

Pancreatic metastases represent 2% of pancreatic tumors. The neoplasms most frequently metastasizing to the pancreas are breast, lung, melanoma and kidney tumors. We present the cases of two patients with pancreatic metastases from renal carcinoma diagnosed 4 and 8 years after the diagnosis and surgical treatment of the primary renal tumor. In both patients, endoscopic ultrasound was useful in the detection and characterization of these pancreatic lesions and allowed fine-needle aspiration for cytological study to be performed

[Clinicopathological characteristics of uninvestigated dyspepsia in Spain]. / Características clinicopatológicas de la dispepsia no investigada en España.

INTRODUCTION: Most patients with uninvestigated dyspepsia are diagnosed with functional dyspepsia. Various types of Helicobacter pylori gastritis have been described, each of which is associated with a distinct natural history of the infection (i.e. a different risk of ulcer or gastric cancer). OBJECTIVE: To determine the clinical and pathological characteristics of patients with uninvestigated dyspepsia in our area and the prevalence of the distinct types of H. pylori gastritis among patients with functional dyspepsia. MATERIAL AND METHODS: Ninety-eight patients (47 men and 51 women, mean age 35.8+/-13 years) with uninvestigated dyspepsia were included in this study. All the patients completed the Dyspepsia-Related Health Scale and all patients underwent gastroscopy with biopsy and the C13-urea breath test. RESULTS: Fourteen patients had organic causes of dyspepsia and 78 had functional dyspepsia. Fifty-one patients with functional dyspepsia (65%) had H. pylori infection; of these, 27 had pangastritis, 21 had antrum-predominant gastritis, 2 had multifocal atrophic gastritis and 1 had normal gastric mucosa. Among uninfected patients, 2 had multifocal atrophic gastritis. CONCLUSIONS: The prevalence of functional dyspepsia in this series was 85%. Twenty-seven percent of patients with functional dyspepsia had a combination of H. pylori infection and antrum-predominant gastritis, the type of gastritis predisposing to duodenal ulcer. Only 5% of the patients had multifocal atrophic gastritis, which is associated with a high risk of gastric cancer.

Características clinicopatológicas de la dispepsia no investigada en España / Clinicopathological characteristics of uninvestigated dyspepsia in Spain

Introducción: La mayoría de los pacientes con dispepsia no investigada son diagnosticados de dispepsia funcional. Se han descrito varios tipos de gastritis por Helicobacter pylori, cada uno de los cuales se asocia a una historia natural diferente de la infección (p. ej., diferente riesgo de enfermedad ulcerosa o de cáncer gástrico). Objetivo: Determinar las características clínicas y patológicas de los pacientes con dispepsia no investigada en nuestra área y la prevalencia de los diferentes tipos de gastritis por H. pylori en los pacientes con dispepsia funcional. Material y métodos: Se incluyó en el estudio a 98 pacientes (47 varones y 51 mujeres, con una media de edad de 35,8 ± 13 años) con dispepsia no investigada. Todos ellos rellenaron el Cuestionario de Calidad de Vida Asociada a Dispepsia, y a todos se les realizó gastroscopia con toma de biopsias y test del aliento con C13-Urea. Resultados: Catorce pacientes tenían causas orgánicas de dispepsia y 78 dispepsia funcional; 51 pacientes con dispepsia funcional (65%) tenían infección por H. pylori y, de ellos, 27 tenía pangastritis, 21 gastritis de predominio antral, 2 gastritis atrófica multifocal y 1 mucosa gástrica normal. Entre los pacientes no infectados, 2 presentaban gastritis atrófica multifocal. Conclusiones: La prevalencia de dispepsia funcional en esta serie fue del 85%. Un 27% de los pacientes con dispepsia funcional presenta la combinación de infección por H. pylori y gastritis de predominio antral, que es el tipo de gastritis que predispone a la aparición de enfermedad ulcerosa duodenal. Sólo un 5% de los pacientes tiene gastritis atrófica multifocal, que es la que se asocia con un riesgo elevado de cáncer gástrico

Introduction: Most patients with uninvestigated dyspepsia are diagnosed with functional dyspepsia. Various types of Helicobacter pylori gastritis have been described, each of which is associated with a distinct natural history of the infection (i.e. a different risk of ulcer or gastric cancer). Objective: To determine the clinical and pathological characteristics of patients with uninvestigated dyspepsia in our area and the prevalence of the distinct types of H. pylori gastritis among patients with functional dyspepsia. Material and methods: Ninety-eigth patients (47 men and 51 women, mean age 35.8 ± 13 years) with uninvestigated dyspepsia were included in this study. All the patients completed the Dyspepsia-Related Health Scale and all patients underwent gastroscopy with biopsy and the C13-urea breath test. Results: Fourteen patients had organic causes of dyspepsia and 78 had functional dyspepsia. Fifty-one patients with functional dyspepsia (65%) had H. pylori infection; of these, 27 had pangastritis, 21 had antrum-predominant gastritis, 2 had multifocal atrophic gastritis and 1 had normal gastric mucosa. Among uninfected patients, 2 had multifocal atrophic gastritis. Conclusions: The prevalence of functional dyspepsia in this series was 85%. Twenty-seven percent of patients with functional dyspepsia had a combination of H. pylori infection and antrum-predominant gastritis, the type of gastritis predisposing to duodenal ulcer. Only 5% of the patients had multifocal atrophic gastritis, which is associated with a high risk of gastric cancer